CLINICAL-RADIOLOGICAL DISSOCIATION IN MULTIPLE SCLEROSIS AND OPTIMIZATION OF ITS THERAPEUTIC MANAGEMENT
Keywords:
multiple sclerosis, immunomodulation, neuro-metabolic therapy, placental hydrolysate, monosialoganglioside, EDSS, HADS, cognitive functionsAbstract
This study evaluates the clinical and immunological parameters of patients with multiple sclerosis and investigates the efficacy of immunomodulatory and neuro-metabolic therapy. A total of 64 patients were examined, including 34 in the clinical-radiological dissociative (CRD) group and 30 in the control group. Assessments based on EDSS and HADS scales showed that the combination therapy (placental hydrolysate and monosialoganglioside GM1) significantly reduced disability levels, improved psycho-emotional status, and helped normalize cognitive functions. Immunological indicators also showed a decrease in IL-6, IL-8, and TNF-α levels. These results confirm that the combined treatment methods are effective in treating multiple sclerosis.
References
Каримова, Д.А. (2017). Тарқоқ склерозда нейроофтальмологик кўрсаткичлар. Офтальмология журнали, 3(1), 28-34.
Каримова, Д.А. (2019). Тарқоқ склерозда кўз тўр пардаси дистрофияси. Офтальмология журнали, 4(2), 35-42.
Мавлиханова, А.А., Павлов, В.Н., Ян, Б., Катаев, В.А., Ван, Н., Аглетдинов, Э.Ф., Кан, Ч.И., Ху, Д. (2018). Моносиалоганглиозид GM1: структура, антиапоптотические свойства и нейропротекция. Медицинский вестник Башкортостана, 13(5), 82-87.
Столярова, И.Д., Бойко, А.Н. (2018). Рассеянный склероз: диагностика, лечение, специалисты. СПб: ЭЛБИСПб.
Шамова, Т.М., Лебейко, Т.Я. (2009). Когнитивные нарушения при рассеянном склерозе. Журнал ГрГМУ, (2), 88.
Havrdova, E., Galetta, S., Stefoski, D., & Comi, G. (2017). Frequent MRI monitoring on the impact of therapy on relapse occurrence in MS. Multiple Sclerosis Journal, 23(6), 725-730.
Okuda, D. (2014). Immunosuppressive treatments in multiple sclerosis. Handbook of Clinical Neurology, 122, 503-511.
Ibanez, C. F. (2017). Jekyll-Hyde neurotrophins: the story of proNGF. Trends in Neurosciences, 25(7), 378-384.
Maier, S. (2020). Interferon-β 1a, an immunomodulator in relapsing remitting multiple sclerosis patients: the effect on pro-inflammatory cytokines. Farmacia, 68, 65-75.
Serafini, B., Rosicarelli, B., Veroni, C., Mazzola, G., & Aloisi, F. (2019). Epstein-Barr Virus-Specific CD8 T Cells Selectively Infiltrate the Brain in Multiple Sclerosis and Interact Locally with Virus-Infected Cells: Clue for a Virus-Driven Immunopathological Mechanism. Journal of Virology, 93.
Kang, S. S., Woo, S. S., Im, J., et al. (2018). Human placenta promotes IL-8 expression through activation of JNK/SAPK and transcription factors NF-kappaB and AP-1 in PMA-differentiated THP-1 cells. International Immunopharmacology, 7(11), 1488-1495.
Kim, Y. S., Park, J. J., Sakoda, Y., et al. (2017). Preventive and therapeutic potential of placental extract in contact hypersensitivity. International Immunopharmacology, 10(10), 1177-1184.
Kappos, L., Polman, C. H., Freedman, M. S., et al. (2017). Treatment of multiple sclerosis with interferon beta-1b during secondary progressive disease: a randomized controlled trial. The Lancet, 357(9268), 1576-1582.
Das, S., Angsantikul, P., Le, C., et al. (2018). Neutralization of cholera toxin with nanoparticle decoys for treatment of cholera. PLoS Neglected Tropical Diseases, 12(2), e0006266.
